Using in-house biocatalysis technology, Seqens has developed direct synthesis of D-Serine, as well as the full range of products in the ketamine family: Hydrochloride and free base, racemic and both chiral pure products, S-Ketamine and R-Ketamine.

Our portfolio of APIs and registered intermediaries synthesized in house include:

  • D-Serine: To increase neuroplasticity and treat schizophrenia (under clinical evaluation)
  • Esmolol HCl: FDA/EMA-approved in 1988 to treat atrial fibrillation
  • Glycopyrrolate Tosylate: An anticholinergic to treat hyperhidrosis (under Clinical evaluation)
  • Mefenamic Acid: A generic analgesic
  • Methoxsalen: A generic antifungal that prevents or treats psoriasis
  • Metolazone: A generic diuretic
  • Norketamine: To treat chronic pain (under development)
  • R-Ketamine HCl: To treat depression, and for pain management (under development)
  • R-Praziquantel: An anthelmintic to treat parasitic worms (under clinical evaluation)
  • S-Ketamine Base: To treat depression, and for pain management (under development)
  • Safinamide: FDA/EMA-approved in 2017 and 2015, respectively, as an add-on treatment for Parkinson’s disease
  • Sodium Benzoate: To treat urea cycle disorders associated with schizophrenia-like symptoms (under clinical evaluation)
  • Toremifene citrate: Antineoplastic chemotherapy FDA/EMA-approved in 1997
    Ursodiol FDA/EMA-approved in 1987 and 1980, respectively, to treat primary biliary cirrhosis

Our location

Address 315 Madison Avenue 3rd Floor - Suite 3007
10017 New York
Phone +1 201 633 0290
Market Pharmaceutical
Mail laurent.alexandre@seqens.com